Galena and NCI to start Phase II trial NeuVax to treat ductal carcinoma in Situ patients

US-based biopharmaceutical firm Galena Biopharma has entered into a collaboration with the National Cancer Institute (NCI) to start a new, Phase II clinical trial with NeuVax (nelipepimut-S) in patients diagnosed with ductal carcinoma in situ (DCIS).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news